traZeneca, Consultant for: Pfizer, AstraZeneca, Proteothera, Celgene, Horizon, P. Khanna Grant/research support from: AstraZeneca, Consultant for: Horizon, Ironwood, Selecta Bio, A. Yeo Consultant for: Horizon Pharma, P. Lipsky Consultant for: AstraZeneca, Celgene, EMD Serono, GSK, Horizon Pharma, Janssen, Medimmune, Pfizer, Roche, Sanofi, UCB
DOI: 10.1136/annrheumdis-2017-eular.4114

THU0450 HOSPITAL READMISSIONS FOR GOUT IN THE UNITED STATES: A NATIONAL DATABASE STUDY

N. Annappureddy¹, A. Saha², P. Poojary^{3,4}, K. Chauhan⁴, G. Nadkarni⁴.
¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville; ²Department of Public Health; ³Department of Public Health; ⁴Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, United States

Background: Gout is associated with significant burden and risk of readmission. Little is known about readmissions among Gout patients on a national level in the United States.
Objectives: The aim of this study was to describe unplanned hospital readmission rates among adult gout patients and assess predictors of readmission.
Methods: We analyzed the 2013 National Readmission Database (NRD) to quantify readmission rates among Gout patients. The NRD includes weighted discharge data from 21 geographically diverse states accounting for 49.3% of the U.S. population. It includes approximately 14 million un-weighted discharges (49.1% of all U.S. discharges) corresponding to 36 million annual discharges nationwide. NRD data is from patients with non-Medicare payers (Medicaid, private, self-pay, or other). Gout hospitalizations were identified using the International Classification of Diseases, ninth Revisions, Clinical Modification (ICD-9-CM) diagnosis code 274.0x. All hospitalizations for patients age ≥18 were included. In efforts to exclude routine readmissions, we excluded those admissions related to pregnancy, those for chemotherapy, admissions where the patient was readmitted the same day as they were discharged, who had deaths during the same index hospitalizations, hospitalizations for less than 24 hours, and those with missing discharge. We utilized Chi-square tests, t tests and Wilcoxon rank-sum tests as appropriate. Survey logistic regression was used to assess the relationship between potential predictors for readmissions and the odds of at least one 30-day unplanned readmission. This analysis was chosen given the NRD data, which involves nested, weighted observations that are inherently stratified in clusters to produce national estimates.
Results: A total of 10708 index hospitalizations which had Gout as the primary diagnosis were included in the analysis. Among those with a primary Gout diagnosis, there were 1212 30-days readmissions (11.3%). 14.3% percent of patients with Gout as the primary diagnosis on index hospitalization were readmitted with the same diagnosis. The next most common readmission diagnoses were congestive heart failure (CHF), septicemia, and acute and unspecified renal failure (Figure 1A). In multivariable analysis of index hospitalizations with Gout as the primary diagnosis, CHF (OR 1.25, 95% CI, 1.05–166), chronic kidney

disease (CKD) (OR 1.54, 95% CI, 1.23–1.92), atrial fibrillation (AF) (OR 1.33, 95% CI, 1.10–1.78), deep venous thrombosis (DVT) (OR 1.29, 95% CI, 1.03–1.88), APR-DRG severity level 3 and 4 (OR 1.51, 95% CI, 1.01–2.38 and OR 2.10, 95% CI, 1.06–4.58), discharge to specialized care (OR 1.47, 95% CI, 1.07–2.02), discharge to home health care (OR 1.35, 95% CI, 1.03–1.77), and discharge against medical advice (OR 3.85, 95% CI, 1.50–9.91), were significantly associated with 30-days readmission after adjusting for demographics, comorbidities, hospital characteristics, payer type, and the APR-DRG severity scale (Figure 1B).
Conclusions: In a national readmissions database, 11.3% of patients admitted with a primary diagnosis of Gout were readmitted within 30 days. Significant predictors of readmission included CHF, CKD, AF, APR-DRG severity level 3 or 4 and any discharge other than routine.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.6468

THU0451 A METHOD FOR COUNTING CALCIUM PYROPHOSPHATE CRYSTALS IN THE SYNOVIAL FLUID

P. Montagna, R. Brizzolara, S. Soldano, M. Cutolo, M.A. Cimmino. Department of Internal Medicine, University of Genova, Genova, Italy

Background: Identification of calcium pyrophosphate dihydrate (CPP) crystals in the synovial fluid (SF) from inflamed joints provides a definitive diagnosis of CPP deposition disease (CPPD) (1). CPP crystals may also be found in non-inflamed joints, allowing diagnosis also during asymptomatic periods (2). SF analysis and CPP crystals count could be used to evaluate disease activity during follow-up. It is more difficult than the count of monosodium urate (MSU) crystals, already tested in a previous work (3), for CPP crystals show different shapes, are often very minute and non-birefringent.
Objectives: To study an objective method for counting CPP crystals in the SF.
Methods: The SFs aspirated from the knees of 15 consecutive patients (8 men) affected by CPPD diagnosed according to the EULAR definition were analysed. Cytological evaluation included SF leukocyte and differential count. For crystal detection, a small drop of fresh SF was placed on a glass slide and examined by compensated polarized microscopy (400x). To facilitate crystal count, the slide was divided into 4 equal parts drawing a cross with a pencil. The count was performed by continuous viewing and for each field both the number of birefringent and non-birefringent crystals was noted. Two observers evaluated separately 6 SFs and repeated the count after 24 hours. SFs were divided into 4 groups: SFs with <50, from 50 to 400, from 401 to 1200, and >1200 crystals.
Results: Mean time needed for the count was 60 minutes. Inter-reader agreement was 0.68 (0.47–0.88) for CPP crystals, 0.68 (0.50–0.85) for the birefringent ones and 0.60 (0.38–0.81) for the non-birefringent. Intra-reader agreement was 0.48 (0.17–0.78) for the first examiner and 0.30 (0.14–0.74) for the second. In 7 patient the SF was aspirated from an inflamed knee. Crystal number did not correlate with the presence of knee inflammation (r=0.41; p=0.19), the SF volume (r=0.14; p=0.61), the number of leukocytes (r=0.36; p=0.19), the % of PMN (r=0.25; p=0.37), and the presence of intracellular crystals (r=0.31, p=0.27). Actively inflamed joints had a higher SF volume [11 ml (10–20 ml) vs. 2 ml (1–10 ml), p=0.03] and a higher percentage of PMN [72% (0–94%) vs. 12% (0–68%), p=0.028]. SF with intracellular crystals showed also a higher percentage of PMN (57.1%±34.3% vs. 3%±6% p=0.006).

Conclusions: Our preliminary results indicate that CPP crystal count is less reliable and more time-consuming than that of MSU crystals. Non-birefringent crystals show lower inter-reader agreement than birefringent ones.
References:
[1] Pascual E. J Rheumatol 1996; 35:306–8.
[2] Martinez A. Arthritis Rheum 1995; 38:S 246.
[3] Montagna P. Reumatismo 2015; 67(1):29–32.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.5045

THU0452 IMMEDIATE AND LONG TERM EFFICACY OF ANAKINRA IN ACUTE FLARES DUE TO HYDROXYAPATITE CALCIFICATIONS: A REAL-LIFE EXPERIENCE OF 13 CASES

P. Zufferey, R. Valcov, A. So. DAL, CHUV, Lausanne, Switzerland

Background: Calcifications composed of hydroxyapatite (HA) crystals can induce acute and severe pain accompanied by signs of acute inflammation. In a previous pilot study, we have shown that anakinra was effective in acute flare of calcific periarthritis of the shoulder in the short term
Objectives: The goal of this retrospective observational study was to confirm these results in a larger set of patients, extending the observation to other localizations and to report on the long-term follow-up.
Methods: All consecutive patients with an acute flare due to HA deposition and treated with anakinra between March 2011 and November 2016 were included. Flare was defined as symptoms of acute pain at rest present for <10 days. None of the patients had corticosteroid therapy in the last 2 weeks, none had responded to at least 48 hours of high doses of NSAIDs or other rheumatologic diseases explaining the symptoms. Clinical evaluation consisted of patient assessment of pain by VAS (10mm scale) at days 0, 1, 3, 21 and joint mobility. CRP and ESR measurements, ultrasound and x-ray examinations were performed before the

treatment and at least once again after the treatment. Anakinra 100mg daily was administered for 1 to 3 consecutive days. Other baseline demographic data and long-term follow up data were collected from the patients' charts and after phone call to the patients

Results: 13 patients fulfilled the inclusion criteria. 12 had a flare at the shoulder, 1 at the first MCP of the hand. The acute inclusion flare was the first episode in 9/13 subjects. At baseline, mean pain VAS:8.8/10 Active and passive motion was severely restricted in all patients. Local inflammation was sufficiently severe to induce an elevation of the CRP and ESR in 10/12 patients. By ultrasound, the mean size of calcifications was 17 mm. Only one had an arc-shaped aspect with shadowing, the others were fragmented. *Short term follow-up:* Pain diminished drastically and rapidly, typically within hours, in most patients after the first injection and was almost absent at day three (mean VAS 1.7/10), stable at 3 weeks (mean VAS: 2.1). At follow-up ultrasound, the calcification disappeared in none of the patients but, in most cases, a reduction (50% mean size reduction) and a fragmentation was observed. *Long term follow-up:* The median duration was 24 months, (range 4 to 74 months). Only 2/ 12 patients experienced an acute relapse. These two patients already suffered from chronic shoulder pain and had prior flares before the treatment with anakinra. Mild chronic pain, essentially related to movement (mean VAS: 2.7), was still present in 5 patients. Two patients regularly took NSAIDs; the others did not use any painkiller

Conclusions: This study suggests that IL-1 β inhibition may be an interesting therapeutic approach in acute flares in relation with hydroxyapatite calcification. Moreover this treatment does not seem to be associated with rebound or recurrence of flares in the long term.

References:

- [1] Zufferey P, So AK. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder *Ann Rheum Dis*. 2013 Mar;72(3):465-7.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2730

THU0453 HEART AND CAROTID CHANGES IN FIFTY-THREE GOUT PATIENTS TREATED WITH XANTHINE OXIDASE INHIBITORS: A FOLLOW-UP STUDY

R.N. Gancheva^{1,2}, A. Kundurdjiev^{1,2}, M. Ivanova^{1,2}, T. Kundurzhiev^{2,3}, Z. Kolarov^{1,2}. ¹Medical Faculty; ²Medical University; ³Faculty of Public Health, Sofia, Bulgaria

Background: Gout connects to cardiovascular (CV) morbidity and higher risk of death due to CV events. A few ultrasound studies assess the way in which heart and vessels change over time in gout patients (pts). It is still unclear whether treatment with allopurinol or febuxostat reduces to some extent target organ damage.

Objectives: We aimed to establish heart and vessels alterations developing over time in gout pts and to find out whether treatment with allopurinol or febuxostat is associated with a change in these structures.

Methods: A total of 53 gout pts were examined and divided into two groups: 31 gouty arthritis without tophi, 24 males and 7 females aged 55.8 $\pm$ 12.3 years and 22 gouty tophi, 20 males and 2 females aged 59 $\pm$ 9 years. Pts underwent multimodal ultrasound examination at study entry and one year and six months thereafter. Aortic root diameter (Ao), left atrium (LA) size, thickness of the interventricular septum (IVS) and of posterior wall (PW) of the left ventricle, end-diastolic volume index (EDVi), end-systolic volume index (ESVi), stroke volume index (SVi), fractional shortening (FS), and ejection fraction (EF) were recorded with 2.5 MHz transducer. Intima-media thickness (IMT) and rigidity of the common carotid arteries, judged by the values of the common carotid artery resistive index (CCARI), were examined with 10 MHz transducer. Statistical analyses were done by chi-square or Fisher's exact test, One-Sample Kolmogorov-Smirnov, Shapiro-Wilk and Paired-Samples T-test. Within-subjects effects and between-subjects effects were assessed by the Repeated Measures ANOVA.

Results: At the two time points of pts' examination there was no deviation in Hb (p=0.412), Ht (p=0.866), serum uric acid (p=0.877), serum albumin (p=0.515), eGFR (p=0.793), EDVi (p=0.248), ESVi (p=0.345), SVi (p=0.357), FS (p=0.516) and CCARI (p=0.244), but PW tended to be thicker (p=0.067). Ao (p=0.008), LA (p=0.001), IVS (p=0.007) increased, and EF (p=0.026) decreased between the two examinations. In gouty arthritis without tophi and in gouty tophi Ao (mean $\pm$ SD; 39.42 $\pm$ 5.00 vs 39.14 $\pm$ 3.77, p=0.471), LA (mean $\pm$ SD; 39.10 $\pm$ 5.11 vs 43.86 $\pm$ 5.95, p=0.088), IVS (mean $\pm$ SD; 12.77 $\pm$ 1.58 vs 13.47 $\pm$ 1.54, p=0.910) and IMT (mean $\pm$ SD; 0.93 $\pm$ 0.17 vs 1.05 $\pm$ 0.17, p=0.237) changed similarly over time, but the reduction in EF was more pronounced in gouty tophi (p=0.031). In pts not taking allopurinol an increase in LA (p=0.012), IVS (p=0.006) and IMT (p<0.001) was registered. In those treated with allopurinol Ao (p=0.011), LA (p=0.022) increased, EF (p=0.016) decreased and no change in IVS (p=0.523) and IMT (p=0.165) was found. Pts who had not received febuxostat tended to have greater Ao (p=0.063), larger LA (p=0.003), thicker IVS (p=0.046), thicker IMT (p<0.001) and lower EF (p=0.034). In contrast, no change was registered in Ao (p=0.559), LA (p=0.332), IVS (p=0.125), EF (p=0.689) and IMT (p=0.163) in treated with febuxostat.

Conclusions: Over time in gouty arthritis without tophi and gouty tophi similar changes in the heart and carotids develop, but heart pumping function is more affected in the later stage of the disease. Heart and carotids morphology and function are preserved in pts treated with febuxostat. In the allopurinol group cardiac morphological and functional alterations occur with no change in IMT.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2516

THU0454 ROLE OF PHYSICAL EXERCISE IN PATIENTS WITH HIP ARTHROPLASTY FOR ASEPTIC NECROSIS OF THE FEMORAL HEAD

R.I. Marcu, S. Patru, A.C. Bighea, D. Matei. *Medical Rehabilitation, University of Medicine and Pharmacy, Craiova, Romania*

Background: Necrosis of the femoral head has a slow but progressive evolution, increasing degradation of the joint, worsening instability, with permanent pain and reduced walk perimeter. In the advanced stages of the disease, the only effective treatment is replacement of the joint (hip arthroplasty).

Objectives: The objective of our study was to examine the effects of a two weeks kinetic program on pain and functional status in patients with hip arthroplasty for aseptic necrosis of the femoral head.

Methods: We conducted an observational, prospective, randomized study on a sample of 47 patients with hip arthroplasty for aseptic necrosis of the femoral head. Patients were randomly assigned to a control group (23 patients) who received only analgesics and NSAID's when needed (group 1) and a study group (24 patients) whose therapeutic program included daily physical exercise (group 2). Patients were initially evaluated and after two weeks of rehabilitation treatment. The clinical and functional parameters assessed were: pain on a visual analogue scale (100 mmVAS), physical impairments (muscular strength and mobility of hip joint) and disabilities (Tinetti Gait Scale, D'Aubigné Scale and movement capacity).

Results: The scores for functional parameters improved: pain- 42.6% (group 2) and 33.4% (group 1) (p=0.00054); physical impairments: muscular strength- 8.3% (group 2), without improving by group 1, mobility: 41.8% (group2) and 21.4% (group 1); disabilities: Tinetti Gait Scale- 33.6% (group 2) and 22.1% (group 1), D'Aubigné Scale- 35.8% (group 2) and 22.4% (group 1), movement capacity- 55.8% (group2) and 31.9% (group 1). The results were statistic significant (p<0.05).

Conclusions: Improvement of pain, physical impairments and disabilities for the study group certifies the efficacy of the rehabilitation program including physical exercise in patients with hip arthroplasty for aseptic necrosis of the femoral head and motivates the continuation of the study on a longer period of time and on a larger number of patients. Rehabilitation program must begin right after patients underwent surgery for hip replacement.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5130

THU0455 RENAL SAFETY OF LESINURAD: A POOLED ANALYSIS OF PHASE III AND EXTENSION STUDIES

R. Terkeltaub¹, R. Malamet², K. Bos², J. Li², D.S. Goldfarb³, M. Pillinger⁴, D. Jalal⁵, J. Hu⁶, K. Saag⁷. ¹University of California, San Diego; ²AstraZeneca Pharmaceuticals, Wilmington; ³New York University School of Medicine; ⁴New York University Langone Medical Center, New York; ⁵University of Colorado Anschutz Medical Center, Aurora; ⁶Formerly Ardea Biosciences, Inc, San Diego; ⁷University of Alabama at Birmingham, Birmingham, United States

Background: Lesinurad (LESU) is a selective uric acid reabsorption inhibitor approved in the United States and European Union at a 200 mg daily dose in combination with a xanthine oxidase inhibitor (XOI) for treatment of hyperuricemia associated with gout in patients unable to achieve target serum uric acid on an XOI (allopurinol or febuxostat) alone.

Objectives: To investigate the renal safety of LESU, data were pooled from 3 pivotal, placebo-controlled, 12-month phase III (core) studies evaluating lesinurad 200 mg (LESU200) and 400 mg (LESU400) in combination with an XOI and from 2 extension studies, where patients continued LESU+XOI at the same dose or were randomized from placebo to LESU200 or LESU400 plus an XOI.

Methods: Renal-related and kidney stone safety data were pooled from core studies to compare LESU200+XOI and LESU400+XOI with an XOI alone and from core studies + extension studies to evaluate the impact on renal safety of extended LESU+XOI treatment. Renal-related treatment-emergent adverse events (TEAEs) were a customized list of 36 preferred terms selected from the Medical Dictionary for Regulatory Activities (MedDRA) Renal and Urinary Disorders System Organ Class (SOC), the Investigations SOC, and the Acute Renal Failure MedDRA Standardized MedDRA Query (SMQ). Descriptive statistics are provided for patients receiving ≥ 1 dose of study medication. To adjust for varying treatment duration, TEAEs are expressed as exposure-adjusted incidence rates (EAIRs; number of subjects with events per 100 person-years).

Results: In the core studies, EAIRs for any renal-related TEAE, serious renal-related TEAEs, and renal-related TEAEs leading to discontinuation were similar with an XOI alone and LESU200+XOI and lower than with LESU400+XOI (Table 1). Similar results were found for kidney stone and serious kidney stone TEAEs. The most common renal-related TEAE was increased serum creatinine (sCr). EAIRs for sCr elevations $\geq 1.5\times$ baseline were higher with LESU+XOI than XOI alone (Table 1). Overall, 75% and 84% of sCr elevations in the XOI alone and LESU+XOI groups, respectively, were resolved at last study assessment; 75% and 66% resolved without interruption of medication. Exposure to extended